Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01856426 | Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects | PHASE1 | COMPLETED | 28 | — | — | Jun 1, 2013 | Oct 1, 2015 | Jan 29, 2016 | 5 | United States, Germany |
Blood will be collected for Hepatitis C viral load at Day 1.
| Arm | Type | Description |
|---|---|---|
| 1- EDP239 | EXPERIMENTAL | EDP239 given once a day. |
| Placebo | PLACEBO_COMPARATOR | 1 treatment arm will be placebo, dose given once a day. |
| 2- EDP239 | EXPERIMENTAL | EDP239 given once a day. |
| 3-EDP239 | EXPERIMENTAL | EDP239 given once a day. |
| 4-EDP239 | EXPERIMENTAL | EDP239 given once a day. |
| Name | Type | Description |
|---|---|---|
| EDP239 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA ≥ 105 IU/mL at the time of screening. * Subjects must have chronic HCV infection as determined by any of the following: * be anti-HCV (+) for at least 6 months per subject history or medical r...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |